Standard

Association of polypharmacy and hyperpolypharmacy with frailty states : A systematic review and meta-analysis. / Palmer, Katie; Villani, Emanuele R.; Vetrano, Davide L.; Cherubini, Antonio; Cruz‑Jentoft, Alfonso J. ; Curtin, Denis; Denkinger, Michael; Gutiérrez‑Valencia, Marta ; Guðmundsson, Adalsteinn; van der Cammen, Tischa; More Authors.

In: European Geriatric Medicine, Vol. 10, No. 1, 2019, p. 9-36.

Research output: Contribution to journalArticleScientificpeer-review

Harvard

Palmer, K, Villani, ER, Vetrano, DL, Cherubini, A, Cruz‑Jentoft, AJ, Curtin, D, Denkinger, M, Gutiérrez‑Valencia, M, Guðmundsson, A, van der Cammen, T & More Authors 2019, 'Association of polypharmacy and hyperpolypharmacy with frailty states: A systematic review and meta-analysis' European Geriatric Medicine, vol. 10, no. 1, pp. 9-36. https://doi.org/10.1007/s41999-018-0124-5

APA

Palmer, K., Villani, ER., Vetrano, DL., Cherubini, A., Cruz‑Jentoft, AJ. ., Curtin, D., ... More Authors (2019). Association of polypharmacy and hyperpolypharmacy with frailty states: A systematic review and meta-analysis. European Geriatric Medicine, 10(1), 9-36. https://doi.org/10.1007/s41999-018-0124-5

Vancouver

Palmer K, Villani ER, Vetrano DL, Cherubini A, Cruz‑Jentoft AJ, Curtin D et al. Association of polypharmacy and hyperpolypharmacy with frailty states: A systematic review and meta-analysis. European Geriatric Medicine. 2019;10(1):9-36. https://doi.org/10.1007/s41999-018-0124-5

Author

Palmer, Katie ; Villani, Emanuele R. ; Vetrano, Davide L. ; Cherubini, Antonio ; Cruz‑Jentoft, Alfonso J.  ; Curtin, Denis ; Denkinger, Michael ; Gutiérrez‑Valencia, Marta  ; Guðmundsson, Adalsteinn ; van der Cammen, Tischa ; More Authors. / Association of polypharmacy and hyperpolypharmacy with frailty states : A systematic review and meta-analysis. In: European Geriatric Medicine. 2019 ; Vol. 10, No. 1. pp. 9-36.

BibTeX

@article{28087ecc298d4c3295454825ddd5ec8c,
title = "Association of polypharmacy and hyperpolypharmacy with frailty states: A systematic review and meta-analysis",
abstract = "Purpose: To investigate: (1) the cross-sectional association between polypharmacy, hyperpolypharmacy and presence of prefrailty or frailty; (2) the risk of incident prefrailty or frailty in persons with polypharmacy, and vice versa. Methods: A systematic review and meta-analysis was performed according to PRISMA guidelines. We searched PubMed, Web of Science, and Embase from 01/01/1998 to 5/2/2018. Pooled estimates were obtained through random effect models and Mantel–Haenszel weighting. Homogeneity was assessed with the I 2 statistic and publication bias with Egger’s and Begg’s tests. Results: Thirty-seven studies were included. The pooled proportion of polypharmacy in persons with prefrailty and frailty was 47{\%} (95{\%} CI 33–61) and 59{\%} (95{\%} CI 42–76), respectively. Increased odds ratio of polypharmacy were seen for prefrail (pooled OR = 1.52; 95{\%} CI 1.32–1.79) and frail persons (pooled OR = 2.62, 95{\%} CI 1.81–3.79). Hyperpolypharmacy was also increased in prefrail (OR = 1.95; 95{\%} CI 1.41–2.70) and frail (OR = 6.57; 95{\%} CI 9.57–10.48) persons compared to robust persons. Only seven longitudinal studies reported data on the risk of either incident prefrailty or frailty in persons with baseline polypharmacy. A significant higher odds of developing prefrailty was found in robust persons with polypharmacy (pooled OR = 1.30; 95{\%} CI 1.12–1.51). We found no papers investigating polypharmacy incidence in persons with prefrailty/frailty. Conclusions: Polypharmacy is common in prefrail and frail persons, and these individuals are also more likely to be on extreme drug regimens, i.e. hyperpolypharmacy, than robust older persons. More research is needed to investigate the causal relationship between polypharmacy and frailty syndromes, thereby identifying ways to jointly reduce drug burden and prefrailty/frailty in these individuals. Prospero registration number: CRD42018104756.",
keywords = "Frail , Prefrail, Polypharmacy , Drugs, Ageing , Medications , Hyperpolypharmacy",
author = "Katie Palmer and Emanuele R. Villani and Davide L. Vetrano and Antonio Cherubini and Alfonso J.  Cruz‑Jentoft and Denis Curtin and Michael Denkinger and Marta  Guti{\'e}rrez‑Valencia and Adalsteinn Gu{\dh}mundsson and {van der Cammen}, Tischa and {More Authors}",
note = "Green Open Access added to TU Delft Institutional Repository ‘You share, we take care!’ – Taverne project https://www.openaccess.nl/en/you-share-we-take-care Otherwise as indicated in the copyright section: the publisher is the copyright holder of this work and the author uses the Dutch legislation to make this work public.",
year = "2019",
doi = "10.1007/s41999-018-0124-5",
language = "English",
volume = "10",
pages = "9--36",
journal = "European Geriatric Medicine",
issn = "1878-7649",
publisher = "Elsevier Masson",
number = "1",

}

RIS

TY - JOUR

T1 - Association of polypharmacy and hyperpolypharmacy with frailty states

T2 - European Geriatric Medicine

AU - Palmer, Katie

AU - Villani, Emanuele R.

AU - Vetrano, Davide L.

AU - Cherubini, Antonio

AU - Cruz‑Jentoft, Alfonso J. 

AU - Curtin, Denis

AU - Denkinger, Michael

AU - Gutiérrez‑Valencia, Marta 

AU - Guðmundsson, Adalsteinn

AU - van der Cammen, Tischa

AU - More Authors, null

N1 - Green Open Access added to TU Delft Institutional Repository ‘You share, we take care!’ – Taverne project https://www.openaccess.nl/en/you-share-we-take-care Otherwise as indicated in the copyright section: the publisher is the copyright holder of this work and the author uses the Dutch legislation to make this work public.

PY - 2019

Y1 - 2019

N2 - Purpose: To investigate: (1) the cross-sectional association between polypharmacy, hyperpolypharmacy and presence of prefrailty or frailty; (2) the risk of incident prefrailty or frailty in persons with polypharmacy, and vice versa. Methods: A systematic review and meta-analysis was performed according to PRISMA guidelines. We searched PubMed, Web of Science, and Embase from 01/01/1998 to 5/2/2018. Pooled estimates were obtained through random effect models and Mantel–Haenszel weighting. Homogeneity was assessed with the I 2 statistic and publication bias with Egger’s and Begg’s tests. Results: Thirty-seven studies were included. The pooled proportion of polypharmacy in persons with prefrailty and frailty was 47% (95% CI 33–61) and 59% (95% CI 42–76), respectively. Increased odds ratio of polypharmacy were seen for prefrail (pooled OR = 1.52; 95% CI 1.32–1.79) and frail persons (pooled OR = 2.62, 95% CI 1.81–3.79). Hyperpolypharmacy was also increased in prefrail (OR = 1.95; 95% CI 1.41–2.70) and frail (OR = 6.57; 95% CI 9.57–10.48) persons compared to robust persons. Only seven longitudinal studies reported data on the risk of either incident prefrailty or frailty in persons with baseline polypharmacy. A significant higher odds of developing prefrailty was found in robust persons with polypharmacy (pooled OR = 1.30; 95% CI 1.12–1.51). We found no papers investigating polypharmacy incidence in persons with prefrailty/frailty. Conclusions: Polypharmacy is common in prefrail and frail persons, and these individuals are also more likely to be on extreme drug regimens, i.e. hyperpolypharmacy, than robust older persons. More research is needed to investigate the causal relationship between polypharmacy and frailty syndromes, thereby identifying ways to jointly reduce drug burden and prefrailty/frailty in these individuals. Prospero registration number: CRD42018104756.

AB - Purpose: To investigate: (1) the cross-sectional association between polypharmacy, hyperpolypharmacy and presence of prefrailty or frailty; (2) the risk of incident prefrailty or frailty in persons with polypharmacy, and vice versa. Methods: A systematic review and meta-analysis was performed according to PRISMA guidelines. We searched PubMed, Web of Science, and Embase from 01/01/1998 to 5/2/2018. Pooled estimates were obtained through random effect models and Mantel–Haenszel weighting. Homogeneity was assessed with the I 2 statistic and publication bias with Egger’s and Begg’s tests. Results: Thirty-seven studies were included. The pooled proportion of polypharmacy in persons with prefrailty and frailty was 47% (95% CI 33–61) and 59% (95% CI 42–76), respectively. Increased odds ratio of polypharmacy were seen for prefrail (pooled OR = 1.52; 95% CI 1.32–1.79) and frail persons (pooled OR = 2.62, 95% CI 1.81–3.79). Hyperpolypharmacy was also increased in prefrail (OR = 1.95; 95% CI 1.41–2.70) and frail (OR = 6.57; 95% CI 9.57–10.48) persons compared to robust persons. Only seven longitudinal studies reported data on the risk of either incident prefrailty or frailty in persons with baseline polypharmacy. A significant higher odds of developing prefrailty was found in robust persons with polypharmacy (pooled OR = 1.30; 95% CI 1.12–1.51). We found no papers investigating polypharmacy incidence in persons with prefrailty/frailty. Conclusions: Polypharmacy is common in prefrail and frail persons, and these individuals are also more likely to be on extreme drug regimens, i.e. hyperpolypharmacy, than robust older persons. More research is needed to investigate the causal relationship between polypharmacy and frailty syndromes, thereby identifying ways to jointly reduce drug burden and prefrailty/frailty in these individuals. Prospero registration number: CRD42018104756.

KW - Frail

KW - Prefrail

KW - Polypharmacy

KW - Drugs

KW - Ageing

KW - Medications

KW - Hyperpolypharmacy

UR - http://www.scopus.com/inward/record.url?scp=85060737204&partnerID=8YFLogxK

U2 - 10.1007/s41999-018-0124-5

DO - 10.1007/s41999-018-0124-5

M3 - Article

VL - 10

SP - 9

EP - 36

JO - European Geriatric Medicine

JF - European Geriatric Medicine

SN - 1878-7649

IS - 1

ER -

ID: 47371939